Data compiled by Redley Lamar · ChainSifter Intelligence
14Suppliers
14Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Pyxis Oncology, Inc. (PYXS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
31Total relationships
3Distinct source URLs
8High confidence
0.760Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from PFE graph: Reciprocal relationship from PYXS graph: Pfizer granted to the Company exclusive worldwide rights under Pfizer's Flexible Antibody Conjugation Technology
Pfizer granted to the Company exclusive worldwide rights under Pfizer's Flexible Antibody Conjugation Technology
PFIZER-INC
PFIZER-INC
92%
The Company paid a combined $25.0 million for the license fee, consisting of an upfront cash payment of $5.0 million and issued 12,152,145 shares of Series B convertible preferred stock, which was co…
BIOSION-USA-INC
BIOSION-USA-INC
90%
the Company obtained an exclusive, worldwide license for development, manufacturing and commercialization rights for BSI-060T, a Siglec-15 targeting antibody
UNIVERSITY-OF-CHICAGO
UNIVERSITY-OF-CHICAGO
85%
the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent
ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
Reciprocal relationship from ADCT graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize …
Reciprocal relationship from AZN graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial …
ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
Reciprocal relationship from BCAX graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from BCAX g…
ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize …
Reciprocal relationship from GILD graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize …
ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
Reciprocal relationship from ADCT graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from ADCT graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from ADCT g…
Reciprocal relationship from AZN graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize o…
ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize …
ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
Reciprocal relationship from GILD graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize …
ons that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failu…
Reciprocal relationship from JNJ graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PYXS graph: ons that later prove to have greater …
Reciprocal relationship from NVSEF graph: Reciprocal relationship from PYXS graph: e dose escalation phase of PYX-201-102 across multiple tumor types with the objective of identifying the Recommended…
e dose escalation phase of PYX-201-102 across multiple tumor types with the objective of identifying the Recommended Phase 2 Dose (RP2D) of MICVO in combination with pembrolizumab. We are currently e…
ABBVIE-INC-ABCURE-INC
ABBVIE-INC-ABCURE-INC
62%
ons that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failu…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
Recommended Phase 2 Dose (RP2D) of MICVO in combination with pembrolizumab. We are currently enrolling and dosing patients across several dose levels between 3.6 mg/kg and 5.4 mg/kg of MICVO, in comb…
Pyxis Oncology, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PYXS-DEBT-11969
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
PYXS-DEBT
Debt stack $18.3M
90%
Market cache reports total debt of $18.3M.
Pyxis Oncology, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Pyxis Oncology, Inc..
Pyxis Oncology, Inc. Ownership
Holder
Name
Confidence
Evidence
PYXS-OWNER-PFIZER-INC
Pfizer Inc
90%
13F overlay lists Pfizer Inc as top holder; 77 tracked holders.
Pyxis Oncology, Inc. Extended Supply Chain Network
